Sai Life Sciences Limited

NSE: SAILIFEPharmaceuticals

Share price

₹1,505.60

-3.60% close of 8 Oct 2026

Market cap ₹31,618 CrP/E 85.9

Business score

How strong the business is, in one number. The parts behind it are in Pro.

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹31,618 Cr

P/E ratio

85.9

P/B ratio

12.9

ROCE

19.6%

ROE

15.4%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹1,675.4052-week low ₹795.00

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 17.7% over the past year, and 22.3% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 18.2% to 29.2% over the last two years.

Whether it grew faster than its sector

It grew 22.3% a year against a sector median of 13.1% — 9.2 percentage points faster.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Priced at 0.4 times its growth rate, on earnings growth of 227%.

	Profit growth	Price per ₹1 profit	Per 1% growth
Sai Life Sciences Limited — this one	227%/yr	85.9×	—
Sun Pharmaceutical	13%/yr	33.4×	₹2.6
Divi's Laboratories	13%/yr	83.3×	₹6.4
Torrent Pharmaceuticals	22%/yr	78.7×	₹3.6
Zydus Lifesciences	32%/yr	23.1×	₹0.72
Laurus Labs Limited	4%/yr	98.6×	₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 41 of 130 on returns, 14 of 127 on growth, 23 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 19.6% on capital, ahead of 68% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Roughly — Over the last five years it made ₹1410 crore of cash from the business and spent about as much on plant and equipment. And the profit is real: of every 100 rupees it reported over 8 years, about 196 arrived as cash — well above the profit; depreciation and interest are the reason, not a windfall. Its cash comes back more slowly than it used to: it went from being waiting 42 days for its cash to waiting 70 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 9 checks clear · 78%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Profit up 22% from a year ago at ₹73 crore, but down 30% from the March quarter

Announced 6 Aug 2026 · Consolidated · Unaudited

Revenue

₹554 Cr

Revenue vs last year

+11.7%

Revenue vs last quarter

-7.9%

Net profit

₹73 Cr

Profit vs last year

+22.1%

Profit vs last quarter

-29.5%

Net margin

13.2%

EPS

₹3.46

Earnings call transcript · 7 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap: ₹31,618 Cr
Prev close: ₹1,505.60
52w High: ₹1,697
52w Low: ₹784
Enterprise value: ₹31,748 Cr
Beta: 1.0
Price CAGR 1y: 83.0%
Price CAGR 3y: —
Price CAGR 5y: —
Price CAGR 10y: —

Ratios

Return on assets: 9.7%
PEG ratio: 0.4
P/E ratio: 85.9
P/B ratio: 12.9
EV / EBITDA: 48.2
Industry P/E: 38.0
ROCE: 19.6%
ROCE 5y average: 10.8%
ROE: 15.4%
Debt / Equity: 0.1
Interest coverage: 12.4
Dividend yield: 0.0%
ROE 3y average: 13.0%
ROE last year: 15.0%

Annual P&L

Annual revenue: ₹2,192 Cr
Annual profit: ₹349 Cr
Operating margin: 29.0%
Net profit margin: 15.9%
EBITDA margin: 28.9%
Sales growth 3y: 21.7%
Sales growth 5y: 23.6%
Profit growth 3y: 227.0%
Profit growth 5y: 42.0%
EPS: ₹16.5
Sales growth TTM: 18.0%
Profit growth TTM: 51.0%
Dividend payout: 0.0%

Quarter P&L

Sales latest quarter: ₹554 Cr
Profit latest quarter: ₹73 Cr
YoY quarterly sales growth: 11.7%
YoY quarterly profit growth: 21.7%
OPM latest quarter: 26.7%

Balance Sheet

Book Value: ₹118
Face Value: ₹1.0
Total debt: ₹288 Cr
Total cash: ₹111 Cr
Borrowings: ₹288 Cr
Reserves / Equity: 117.3

Cash Flow

Operating cash flow: ₹509 Cr
Free cash flow: -₹83 Cr
FCF yield: -0.4%
Net cash flow: -₹9 Cr

Shareholding

Promoter holding: 34.5%
FII holding: 19.9%
DII holding: 32.3%
Public holding: 13.3%

Peer comparison

Company	Price ₹	P/E	Mkt cap ₹ Cr	Div yield %	Profit qtr ₹ Cr	Profit var %	Sales qtr ₹ Cr	Sales var %	ROCE %
Sun Pharma.Inds.	1,758.00	33.3	4,21,803	0.90	2,901.2	6.0	15,299.9	10.5	20.5
Divi's Lab.	9,434.00	84.0	2,50,443	0.31	902.0	65.5	3,080.0	27.8	22.0
Torrent Pharma.	4,631.20	79.0	1,76,156	0.81	566.0	5.8	4,921.0	54.9	15.2
Zydus Lifesci.	1,115.90	22.9	1,11,311	0.09	990.2	-35.1	8,017.0	22.0	21.1
Laurus Labs	2,021.30	99.9	1,09,213	0.10	362.1	125.5	2,026.3	29.1	17.8
Cipla	1,302.00	29.4	1,05,185	0.98	785.6	-39.2	7,119.3	2.3	15.5
Mankind Pharma	2,393.75	46.3	98,873	0.04	574.1	29.6	4,030.6	12.9	13.5
Sai Life	1,513.50	87.4	32,150	0.00	73.3	21.2	554.3	11.7	19.6
Median	414.00	34.1	2,123	0.07	13.5	29.5	164.0	18.4	15.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026

Line item	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	642	384	439	280	396	440	580	496	537	556	602	554
Expenses		287	315	254	293	320	422	375	392	369	426	406
Material Cost								160	204	114	159	178
Change in Inventories								-18	-63	14	2.52	-33
Purchases of Stock-in-Trade								0	0	0	0	0
Employee Cost								161	163	173	187	180
Other Expenses								74	89	68	77	81
Operating Profit		96	125	26	102	120	158	121	146	188	177	148
OPM %	10	25	28	9.34	26	27	27	24	27	34	29	27
Other Income		11	3	8	10	9	10	10	15	0	16	4
Exceptional items (within Other Income)								0	0	-8.29	0.29	0
Interest		23	21	21	21	23	11	12	9	10	8	8
Depreciation		31	31	31	36	34	37	38	40	44	45	46
Profit before tax		53	76	-18	55	72	119	81	112	134	139	98
Tax %		25	26	-25	25	25	26	25	25	25	25	25
Net Profit		40	56	-14	42	54	88	60	84	100	104	73
EPS in Rs						2.59	4.24	2.90	4	4.75	4.92	3.45
Diluted EPS in Rs								2.83	3.93	4.71	4.87	3.42

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026

Line item	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	695	726	760	870	1,217	1,465	1,695	2,192	2,250
Expenses	520	558	593	743	1,048	1,178	1,285	1,559	1,592
Material Cost								578
Change in Inventories								-7.22
Purchases of Stock-in-Trade								0
Employee Cost								683
Other Expenses								307
Operating Profit	176	168	167	126	169	287	410	634	658
OPM %	25	23	22	15	14	20	24	29	29
Other Income	6	18	27	28	27	29	35	40	35
Exceptional items (within Other Income)								-8.00
Interest	24	22	33	54	81	88	78	41	35
Depreciation	44	55	80	90	99	119	139	167	175
Profit before tax	113	109	82	10	16	109	228	466	483
Tax %	35	30	25	36	39	24	25	25
Net Profit	73	76	61	6	10	83	170	349	362
EPS in Rs							8.16	16	17
Diluted EPS in Rs								16
Dividend Payout %	0	0	0	1,117	676	0	0	0

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years: —
5 years: 24%
3 years: 22%
TTM: 18%

Compounded profit growth

10 years: —
5 years: 42%
3 years: 227%
TTM: 51%

Stock price CAGR

10 years: —
5 years: —
3 years: —
1 year: 83%

Return on equity

10 years: —
5 years: 9%
3 years: 13%
Last year: 15%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated

Line item	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	16	16	17	18	18	18	21	21
Reserves	703	778	845	861	870	957	2,108	2,463
Borrowings	249	304	637	752	933	928	352	288
Other Liabilities	247	312	318	527	358	359	665	841
Total Liabilities	1,215	1,410	1,817	2,157	2,179	2,262	3,146	3,613
Fixed Assets	373	641	701	751	1,037	1,180	1,488	1,815
CWIP	116	91	246	410	151	107	124	270
Investments	0	0	0	0	2	2	2	50
Other Assets	726	679	870	997	989	973	1,531	1,477
Total Assets	1,215	1,410	1,817	2,157	2,179	2,275	3,160	3,626

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated

Line item	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	129	116	-36	105	219	263	314	509
Cash from Investing Activity	-158	-262	-260	-102	-99	-191	-536	-395
Cash from Financing Activity	268	-4	296	72	-201	-95	301	-124
Net Cash Flow	239	-150	-1	75	-80	-24	79	-9
Free Cash Flow	-28	-157	-298	-102	148	82	-55	-83

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated

Line item	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	123	136	99	102	85	64	76	62
Inventory Days	86	79	127	179	121	72	93	97
Days Payable	207	258	230	279	180	113	253	182
Cash Conversion Cycle	1	-43	-4	2	25	22	-83	-24
Working Capital Days	55	24	62	42	36	12	66	70
ROCE %		13	9	3	6	11	14	20

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Sep 2026

Line item	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	35	35	35	35	35	35	35	35
FIIs	12	12	15	23	21	21	20	20
DIIs	12	13	22	30	31	32	33	32
Public	41	39	29	13	12	13	13	13
No. of Shareholders	1,81,122	1,40,677	1,26,380	1,19,705	1,14,820	1,17,527	1,25,096	1,43,124

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +76.8% (₹851.55 → ₹1,505.60)Brick size ₹53.75 (fixed)Bricks 22

Price moved up one brickPrice moved down one brickLast close ₹1,505.60 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

130inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

56,57,451inr

2026-03-31

News

News and filings about Sai Life Sciences Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

catalysts including homogeneous catalysts
iodine
lithium
packing materials
raw materials, chemicals and reagents
solvents
stores and spares

Depends on the price of

fuel

Sells to

Auron Therapeutics · discovery biology services
Eikonizo Therapeutics · drug discovery / R&D services
GSK · two commercial intermediates for gepotidacin/Blujepa (~$17mn exports current year)
Schrodinger, Inc. · integrated discovery work via Sai Schrodinger Research Laboratories (medicinal/synthetic c…

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector: Healthcare
Industry: Pharmaceuticals
Classification: Healthcare › Pharmaceuticals
ISIN: INE570L01029

Plants

Bidar manufacturing facility (Kolhar Industrial Area)
Bollaram intermediate manufacturing facility
Discovery Biology Laboratory
Hyderabad integrated R&D / CMC campus (IKP Knowledge Park, Turkapally, Shameerpet/Genome Valley)
Manchester research facility

News impact

Big market events that reach Sai Life Sciences Limited, and how the effect spreads.

29 Sept, 00:07 IST · Market event · high impact

US waives tariffs on certain speciality drugs from 20 countries, including India - Moneycontrol.com

The US waived tariffs on certain speciality drugs from 20 countries including India, which helps Indian drug exporters like Sun Pharma by keeping US sales cheap and hurts no one directly.

Healthcare

Who it hits first

The United States waived import tariffs on certain speciality drugs shipped from 20 countries, including India, just ahead of a threatened 100% tariff on pharmaceuticals.
Indian makers of speciality and generic drugs — led by Sun Pharmaceutical (India's largest drug maker), Dr Reddy's Laboratories, and Cipla — can keep selling into the US without a sudden cost jump.
The relief is narrow (only certain speciality drugs) and comes with the bigger tariff threat still hanging, so the gain is real but capped.

Who may gain

Sun Pharmaceutical (India's largest drug maker) — biggest US speciality and generic sales base to protect.
Dr Reddy's Laboratories (generic and speciality drug maker) — keeps US pricing intact.
Cipla (respiratory and generic drug maker) — same US cost relief.
Divi's Laboratories (bulk-drug ingredient maker) — supplies all three named exporters, so steadier US orders flow upstream.
Laurus Labs (drug-ingredient and contract maker) — supplies Dr Reddy's and Cipla.
Biocon (biologics maker) — speciality-biologic sales get tariff shelter, though weak profits limit the cheer.

Along the supply chain

Downstream

Downstream, US distributors and patients see no price jump on the covered speciality drugs, so demand stays steady rather than shifting to other countries' suppliers.

Upstream

Upstream makers of drug ingredients benefit second-hand: Divi's Laboratories supplies Sun Pharma, Dr Reddy's, and Cipla, and Laurus Labs supplies Dr Reddy's and Cipla, so steadier US formulation sales support their order books.

Where demand moves

Business

US buyers keep ordering Indian speciality drugs at tariff-free prices instead of cutting back or switching suppliers, so export volumes and margins for Sun Pharma, Dr Reddy's, and Cipla hold up.

Capital

Investors re-rate US-exposed pharma shares as the near-term tariff shock is removed, pulling money back into large exporters and their ingredient suppliers.

How it spreads across sectors

Healthcare

Positive but narrow — US-facing drug exporters and their ingredient suppliers gain, while domestic hospitals and labs feel nothing.

When it plays out

Immediate

In 1-7 days, US-exposed pharma shares likely bounce as the tariff threat lifts and exporters confirm coverage.

Medium term

In 1-6 months, the benefit lasts only if the waiver holds and the broader tariff stays away; any widening of US drug tariffs reverses it.

Short term

In 1-4 weeks, gains settle as investors check which speciality drugs are covered and watch the threatened 100% tariff's next move.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Splits, bonuses & buybacks

daily-prices repair: 3 rows from NSE's archive (replace 1, delete 1, insert 1), 2025-03-18..2026-02-01 (docs/flat_day_repair.md)1× · 18 Mar 2025

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.